Compare HRTX & MASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRTX | MASS |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.8M | 228.8M |
| IPO Year | 2007 | 2020 |
| Metric | HRTX | MASS |
|---|---|---|
| Price | $0.94 | $7.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.50 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.8M | 250.3K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.47 |
| EPS | N/A | ★ 0.54 |
| Revenue | ★ $154,904,000.00 | $56,197,000.00 |
| Revenue This Year | $15.28 | $19.44 |
| Revenue Next Year | $20.29 | $18.63 |
| P/E Ratio | ★ N/A | $13.33 |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $0.74 | $4.20 |
| 52 Week High | $2.61 | $9.34 |
| Indicator | HRTX | MASS |
|---|---|---|
| Relative Strength Index (RSI) | 56.47 | 68.17 |
| Support Level | $0.74 | $5.86 |
| Resistance Level | $1.41 | $7.42 |
| Average True Range (ATR) | 0.06 | 0.33 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 84.74 | 82.17 |
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.